India’s pharmaceutical industry stands at the crossroads of a period rich with opportunity and uncertainty as businesses are confronted by the need to generate growth in a mature, competitive market while faced with increasing pricing pressures, evolving government regulations and protectionist policies.

As the world’s third-largest pharmaceutical industry by volume, this sector has borne witness to a remarkable influx of private investment, particularly within the API (Active Pharmaceutical Ingredients) segment and the broader domain. With clear interest in revenue growth, trends toward deregulation and government incentives and policies (PLI, SPI, Bulk Drug Parks and PTUA Schemes), India is clearly looking at this sector as a core driver of growth.

ELP’s pharmaceutical offering includes a multi-disciplinary team of experts from its corporate, regulatory, international trade, tax, anti-trust, white collar crimes and disputes teams. Working with both domestic and multinational companies, we have a deep understanding of the legal and regulatory landscape governing the pharmaceutical industry in India, as well as the unique business and ethical considerations that come with this sector.

Our services include:

• Support in leveraging ‘Make in India’ policies
• Assistance in Green Field projects
• Acquisition and development of real estate assets, including greenfield and brownfield facilities
• Strategic M&A’s and Joint Ventures
• Dispute resolution in every forum, including litigation and arbitration
• Advisory on Merger Controls ; Anti -Competitive Agreements; Abuse of Dominant Position
• Government Affairs and Regulatory
• Tax Optimization, Disputes and Advocacy
• End to end assistance on customs related issues
• Advisory on BIS/Quality Controls
• Advisory on Trade Advocacy/Trade Remedial/Sanctions
• Adherence to ESG norms
• White Collar Crimes/Forensic investigations/Criminal matters